Rivus Pharmaceuticals begins patient dosing in Phase II AMPLIFY trial
Rivus Pharmaceuticals has dosed the first patients in the AMPLIFY Phase II clinical trial evaluating HU6, an investigational oral therapy …
Post
-
-
GlycoNex secures Japan’s PMDA approval for GNX1021 Phase I trial
GlycoNex has received Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) approval to commence a first-in-human Phase I clinical trial of …
-
OCT East Coast 2026: overcoming FDA volatility and global uncertainty
Since the Trump Administration reclaimed the White House a little over a year ago, several changes with global consequences have …
-
Lilly’s Jaypirca racks up fourth Phase III CLL win
Eli Lilly’s Jaypirca (pirtobrutinib) has succeeded in its fourth Phase III trial in chronic lymphocytic leukaemia (CLL). The Phase III BRUIN …
-
IDEAYA reports top line data from Phase II/III trial of darovasertib combo
IDEAYA Biosciences and Servier have reported positive top line results from the Phase II/III registration trial, OptimUM-02, assessing darovasertib in …
-
FDA cracks down on sponsor and researchers’ failure to publish trial data
The US Food and Drug Administration (FDA) has reminded more than 2,200 sponsors and researchers to publicly publish their clinical …
-
Vir Biotechnology doses first patient in Phase I VIR-5500 trial
Vir Biotechnology has dosed the first patient in one of three expansion cohorts in its ongoing Phase I clinical trial …
-
Spyre stock soars as UC drug touts Entyvio-rivalling potential
Spyre Therapeutics’ stock is up nearly 30% after its ulcerative colitis (UC) candidate has demonstrated competitive remission-prompting potential during a …
-
Never-married individuals reported to have higher cancer risk
Cancer is the leading cause of death globally, accounting for one in six deaths worldwide in 2020, according to the …
-
AbbVie’s Elahere succeeds in Phase II platinum-sensitive ovarian cancer trial
AbbVie’s Elahere has shown a 62.7% objective response rate (ORR) in patients with platinum-sensitive ovarian cancer (PSOC) in a Phase …
-
GSK announces positive outcomes from Phase I BEHOLD-1 trial of Mo-Rez
GSK has shared encouraging data from its Phase I BEHOLD-1 clinical trial of mocertatug rezetecan (Mo-Rez), an antibody-drug conjugate targeting …
-
Preparation is key to understanding global trade compliance for trials
For global studies, investigational material and active pharmaceutical ingredients (API) are often shipped to sites in different countries from a …
-
BioNTech and DualityBio report positive data for trastuzumab pamirtecan
BioNTech and DualityBio reported encouraging data from a Phase II cohort of their global clinical study evaluating the efficacy of …
-
OCT Europe 2026: tackling clinical trial complexities with innovation and partnerships
Regulatory changes, geopolitical pressures and technological advancements are among the factors currently driving new and evolving challenges within the clinical …
-
Verastem Oncology’s combo shows two-year durability in ovarian cancer
Verastem Oncology’s combination therapy has shown durability in patients with recurrent low-grade serous ovarian cancer (LGSOC). The data, presented during an …
